CLINICAL TRIALS PROFILE FOR ABSTRAL
✉ Email this page to a colleague
All Clinical Trials for Abstral
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01158820 ↗ | Alternative Sedation During Bronchoscopy | Completed | Hospira, Inc. | Phase 4 | 2010-06-01 | This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure. |
NCT01158820 ↗ | Alternative Sedation During Bronchoscopy | Completed | Hospira, now a wholly owned subsidiary of Pfizer | Phase 4 | 2010-06-01 | This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure. |
NCT01158820 ↗ | Alternative Sedation During Bronchoscopy | Completed | University of Pennsylvania | Phase 4 | 2010-06-01 | This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure. |
NCT01315886 ↗ | Conversion From Fast Acting Oral Opioids to Abstral® | Terminated | Orexo AB | Phase 4 | 2011-02-21 | The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer pain (BTcP). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Abstral
Condition Name
Clinical Trial Locations for Abstral
Trials by Country
Clinical Trial Progress for Abstral
Clinical Trial Phase
Clinical Trial Sponsors for Abstral
Sponsor Name